RxNews Recap for Tuesday 12-01-09 Print E-mail
By Mary Davila   
Tuesday, 01 December 2009 21:08
Below is a list of the companies that made news in the healthcare sector on Tuesday, December 01, 2009.

Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

Provectus Pharmaceuticals, Inc. (OTCBB:PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced preliminary data for the company’s PH-10 Phase 2 clinical trial for Psoriasis as well as for its Phase 2 clinical trial for Atopic Dermatitis.

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA), today announced the submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for XM02, a granulocyte colony-stimulating factor (G-CSF) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

Helicos BioSciences Corporation (NASDAQ:HLCS) today announced the publication of a landmark study by Dr. Bradley Bernstein of the Massachusetts General Hospital describing the use of Helicos’ single molecule sequencing technology for the performance of genome-wide, epigenomic experiments using minute amounts of nucleic acid.

Genzyme Corporation (NASDAQ:GENZ) announced today that it has begun shipping vials of newly produced Cerezyme® (imiglucerase for injection) manufactured t its Allston Landing plant.

The Medicines Company (NASDAQ: MDCO) announced today that it has received European approval for the use of Angiox® (bivalirudin) as an anticoagulant in patients with heart attacks (so-called ST-segment elevation myocardial infarction (STEMI)) undergoing emergency heart procedures called primary percutaneous coronary intervention (PCI).

Provectus Pharmaceuticals, Inc. (OTCBB:PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced preliminary data for the company’s PH-10 Phase 2 clinical trial for Psoriasis as well as for its Phase 2 clinical trial for Atopic Dermatitis.

BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the details of its worldwide Direct Response Television (DRTV) strategy to further enhance its international marketing efforts for its award-winning, pain relieving ActiPatch and Allay brands.

Agilent Technologies Inc. (NYSE:A) and Fasteris SA today announced that Fasteris has been named the first European Certified-Service Provider (CSP) for Agilent’s SureSelect Target Enrichment System for next-generation sequencing.

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Schering-Plough HealthCare Products, Inc.’s, New Drug Application (NDA) for ZEGERID OTC™ Capsules (omeprazole/sodium bicarbonate) with a dosage strength of 20 mg of omeprazole for over-the-counter (OTC) treatment of frequent heartburn. Schering-Plough and Merck & Co., Inc. merged on November 3, 2009.

Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that Mr. William R. Keller has been appointed a Director of Alexion, effective immediately. With Mr. Keller’s appointment, there are now eight members of Alexion’s Board of Directors.

Dyax Corp. (NASDAQ:DYAX) announced today that the U.S. Food and Drug Administration (FDA) has granted approval for KALBITOR® (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.

GLG Life Tech Corporation (TSX:GLG)(NASDAQ:GLGL) ("GLG" or the "Company"), the vertically integrated leader in the agricultural and industrial development of high quality stevia extracts, announced today that the underwriters of its recently completed equity offering (the "Offering") have purchased an additional 543,750 common shares from the Company at the public offering price of US$7.60 per share for gross proceeds of US$4,132,500 in connection with the closing of the full amount of the underwriters' over-allotment option.

VIVALIS (NYSE Euronext Paris: VLS), a biopharmaceutical company that provides the pharmaceutical industry with innovative cell-based solutions for the manufacture of vaccines and proteins and develops drugs to prevent and treat viral diseases, announces today that its stock will enter the CAC Small 90 and SBF 250 indexes.

Lawrence A. Siebert, Chairman and CEO of Chembio Diagnostics, Inc. (OTCBB:CEMI), a company that develops, manufactures, licenses, and markets proprietary rapid diagnostic tests, has appeared in interviews conducted by FOX News and Sirius Satellite Radio that were broadcast today.

Neogen Corporation (Nasdaq: NEOG) announced today that it has acquired the BioKits food safety business of San Diego, Calif.-based Gen-Probe Incorporated ( GPRO).

CEL-SCI Corporation (NYSE Amex: CVM), a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today that it has retained the services of an international Contract Research Organization (CRO) to run CEL-SCI's upcoming Phase III clinical trial in advanced primary head and neck cancer with the Company's lead product candidate, Multikine®.This CRO is considered to be one of the world's top CRO's for running global oncology studies.

Stem Cell Therapy International Inc. (OTCBB:SCII) announced that it has signed an agreement with Histostem Ltd. of South Korea ("Histostem"), for the exclusive, worldwide rights to the distribution of the Company's existing SteMixx line of stem cell based cosmetic products, as well as future products under development. Previously available for purchase only in Korea, SteMixx received approval last month from the Korean FDA as an effective cosmetic for the treatment of aging skin.

SCOLR Pharma, Inc. (NYSE Amex: DDD) announced that on November 20, 2009 it licensed to Chrono Nutraceuticals LLC exclusive rights in Canada to manufacture and sell four extended release dietary supplements using SCOLR's proprietary CDT® drug delivery platform.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus